ASLAN CEO Carl Firth On A New Paradigm for Drug Development In Asia: An Interview With PharmAsia News

Asia continues to increase in importance for global clinical trial programs. Big pharmas such as Novartis and AstraZeneca are building up their own R&D sites while Eli Lilly and Pfizer are creating virtual R&D networks, taking advantage of the large naïve patient population and other efficiencies in Asia to accelerate drug development.